Literature DB >> 18274173

Supervised exercise therapy for intermittent claudication.

B L W Bendermacher1, L M Kruidenier, S P A Nicolaï, R J Th J Welten, J A W Teijink.   

Abstract

PURPOSE OF THE REVIEW: Although exercise therapy is considered to be of significant benefit to people with intermittent claudication, almost half of those affected do not undertake any exercise therapy. The purpose of this review is to evaluate the effects of supervised exercise therapy (SET) for people with intermittent claudication.
MATERIALS AND METHODS: SET will be compared with non-supervised exercise therapy programs and the superiority of SET will be demonstrated. The development and implementation of a new community-based concept of SET will be addressed, whereas the first results of this new concept will be presented and compared with the results of SET programs provided in clinical settings, as described in literature. MAIN
RESULTS: SET programs have significant benefits compared with non-supervised programs. Community-based SET has both economic and logistic advantages over clinic-based SET. Furthermore, community-based SET programs seems to be as effective as SET provided in a clinic-based setting and is a promising approach to providing conservative treatment for patients with intermittent claudication.
CONCLUSIONS: SET in a community-based setting should ideally be the initial standard of care for patients with intermittent claudication. However, a study of the cost-effectiveness should be awaited.

Entities:  

Mesh:

Year:  2007        PMID: 18274173     DOI: 10.1080/00015458.2007.11680135

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  1 in total

1.  Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in patients with peripheral arterial disease.

Authors:  Magdalena Pilz; Elisabeth Kandioler-Honetz; Alfa Wenkstetten-Holub; Waltraud Doerrscheidt; Rudolf Mueller; Robert Wolfgang Kurz
Journal:  Wien Klin Wochenschr       Date:  2014-05-14       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.